Oncimmune, the Nottingham immunodiagnostics group, has successfully raised approximately £2.1 million through a capital raise.
It has been achieved through the placing of 2,044,446 shares with existing and new investors and through subscriptions for 2,622,221 shares.
The net proceeds of approximately £1.9 million, will be used to retire a proportion of the company’s existing debt facility, provide the company with additional near-term working capital, and fund future collaborations in biomarker tool development.
Since announcing the capital raising, Oncimmune has signed further ImmunoINSIGHTS contracts with a combined value of approximately $1.25 million with an existing global pharmaceutical client.
